ASLAN Pharmaceuticals moves Taiwan office

Published: 15-May-2017
Pharmaceutical

New location will support growing business in Taiwan and the Asia region, strengthening the company’s local presence

ASLAN Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia-prevalent tumour types, will move to a new office in Taiwan with immediate effect.

The new location will allow ASLAN to support its growing business in Taiwan and the Asia region, further strengthening the company’s capabilities and local presence.

The Taiwan office is one of three regional offices in Asia Pacific that drives ASLAN’s clinical development strategy in the region. ASLAN has operational presence in Singapore, China and Australia.

The address of the new office is:

ASLAN Pharmaceuticals Taiwan, 35F, 68 Zhongxiao East Road Section 5, Xinyi District, Taipei 110, Taiwan.

  • Companies:
  • Aslan Pharmaceuticals
See more

You may also like

Pharmaceutical

ASLAN and BioGenetics sign second commercialisation agreement

Read more
The partnership will see BioGenetics market ASLAN's DHODH in South Korea

Trending Articles

  1. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  2. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  3. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  4. Production of pharmaceutical compounds through microbial fermentation Most people’s experience of fermentation will be through its most famous and popular use – the brewing of beer
  5. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Pharmaceutical

ASLAN and BioGenetics sign second commercialisation agreement

The partnership will see BioGenetics market ASLAN's DHODH in South Korea
Ingredients

Therapeutics: anticancer agent: varlitinib

Human epidermal growth factors (HERs) are a group of receptors that are mutated or overexpressed in many tumour types; HER2 is the most familiar, as the target of the breast cancer antibody trastuzumab, but it is not alone
Regulatory

Aslan announces shortened timeline to commercialisation for varlitinib

Aslan Pharmaceuticals announced that commercialisation of varlitinib in China, if approved, is expected to begin approximately one year earlier than previously anticipated
Regulatory

Aslan Pharmaceuticals receives IND approval by Singapore’s Health Sciences Authority

ASLAN Pharmaceuticals, announced the approval of its investigational new drug (IND) application by Singapore’s Health Sciences Authority to initiate a phase 2 study of ASLAN003 for the treatment of acute myeloid leukaemia (AML)
Finance

Aslan pharmaceuticals receives approval to list on Taipei exchange

Biotech company ASLAN Pharmaceuticals has received approval from the Board of Taipei Exchange to list on TPEx
Design & Build

ASLAN Pharmaceuticals opens China office

Company's first office in China will complement its existing presence in Singapore and Taiwan
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Subscribe now